Exscientia Takes AI Specialist Allcyte

UK-based pharmatech Exscientia has entered into a binding agreement to buy Vienna-based Allcyte, a specialist in precision medicine using artificial intelligence (AI). Under the terms, Exscientia will pay €50 million, comprised of cash and Exscientia’s ordinary shares. The transaction is currently under review by Austrian regulators.

Allcyte’s technology uses AI to analyze drug activity in live patent samples at single-cell resolution. According to Exscientia, Allcyte’s AI platform is the first to have been clinically validated to improve cancer patient outcomes.

Exscientia said the acquisition expands its translational capabilities by enabling high content evaluation of individual patient biology in primary tumor tissues, rather than artificial cell lines or animal models.

“Allcyte is able to demonstrate what therapy actually works in the individual patient with the most disease relevant screening platform we have seen,” said Andrew Hopkins, Exscientia’s CEO.  “Combining Allcyte’s platform with Exscientia’s technologies can redefine how drugs are developed, enabling integrated discovery and patient selection.”

Once the takeover has completed, Exscientia will “significantly” expand and extend Allcyte’s platform into early discovery, adding that it also plans to expand the Vienna site as its hub in the EU.

Author: Elaine Burridge, Freelance Journalist

UK-based Exscientia has agreed to buy Allcyte, a specialist in precision...
UK-based Exscientia has agreed to buy Allcyte, a specialist in precision medicine using artificial intelligence (AI), for €50 million. Located in Vienna, Austria, Allcyte’s technology uses AI to analyze drug activity in live patent samples at single-cell resolution. (c) Exscientia

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.